- Home
- DMAC
DMAC
DiaMedica Therapeutics Inc.
as 04-25-2025 3:35pm EST
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | MINNEAPOLIS |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $8.00 | AVG Volume (30 days): | 90.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.60 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.14 - $6.82 | Next Earning Date: | 05-07-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest DiaMedica Therapeutics Inc. News
DMAC Breaking Stock News: Dive into DMAC Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely
GuruFocus.com
a month ago
DiaMedica Therapeutics Inc (DMAC) Q4 2024 Earnings Call Highlights: Strong Financial Position ...
Thomson Reuters StreetEvents
a month ago
Q4 2024 DiaMedica Therapeutics Inc Earnings Call
Business Wire
a month ago
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial Results
Simply Wall St.
a month ago
Insider Stock Buying Reaches US$9.00m On DiaMedica Therapeutics
Business Wire
2 months ago
DiaMedica Therapeutics to Report Fourth Quarter 2024 Financial Results and Provide a Business Update March 18, 2025
Business Wire
2 months ago
DiaMedica Therapeutics Appoints Daniel J. O’Connor to the Board of Directors
Business Wire
2 months ago
DiaMedica Therapeutics Announces Publication of DM199’s Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal Stroke
Compare DMAC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DMAC DiaMedica Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.